OBJECTIVES: To determine the frequencies of HLA-B alleles in Ugandan patients in the NORA substudy of the DART trial and to compare HLA-B allele frequencies in those with and without clinically diagnosed hypersensitivity reaction (HSR). METHODS: DNA-based HLA-B genotyping was used to determine HLA alleles in 247 participants who received abacavir, including all six participants ('cases') with clinically diagnosed abacavir HSR. RESULTS: The incidence of clinical abacavir HSR in this double-blinded study was 2.0% (6/300) in the abacavir group. As HLA-B*5701 was absent throughout the entire cohort, including the six HSR 'cases', an association could not be established between HLA-B*5701 and clinically diagnosed abacavir HSR. No other HLA-B*57 alleles were present among the six 'cases'. HLA-B*5703 was the most frequent HLA-B*57 allele among the abacavir-tolerant participants. CONCLUSION: The rate of clinical HSR was low, which may reflect the expected 2-3% clinical false-positive rate seen in previous double-blind randomized studies. The presumption that these cases may be false-positive abacavir HSR is supported by the fact that no HLA-B*5701 alleles were found in the abacavir group. Implementation of prospective HLA-B*5701 screening must be based on benefit/risk considerations within local practice. Clinical risk management remains paramount.
OBJECTIVES: To determine the frequencies of HLA-B alleles in Ugandan patients in the NORA substudy of the DART trial and to compare HLA-B allele frequencies in those with and without clinically diagnosed hypersensitivity reaction (HSR). METHODS: DNA-based HLA-B genotyping was used to determine HLA alleles in 247 participants who received abacavir, including all six participants ('cases') with clinically diagnosed abacavir HSR. RESULTS: The incidence of clinical abacavir HSR in this double-blinded study was 2.0% (6/300) in the abacavir group. As HLA-B*5701 was absent throughout the entire cohort, including the six HSR 'cases', an association could not be established between HLA-B*5701 and clinically diagnosed abacavir HSR. No other HLA-B*57 alleles were present among the six 'cases'. HLA-B*5703 was the most frequent HLA-B*57 allele among the abacavir-tolerant participants. CONCLUSION: The rate of clinical HSR was low, which may reflect the expected 2-3% clinical false-positive rate seen in previous double-blind randomized studies. The presumption that these cases may be false-positive abacavir HSR is supported by the fact that no HLA-B*5701 alleles were found in the abacavir group. Implementation of prospective HLA-B*5701 screening must be based on benefit/risk considerations within local practice. Clinical risk management remains paramount.
Authors: Guinevere Q Lee; Suzanne McCluskey; Yap Boum; Peter W Hunt; Jeffrey N Martin; David R Bangsberg; Xiaojiang Gao; P Richard Harrigan; Jessica E Haberer; Mark J Siedner Journal: J Acquir Immune Defic Syndr Date: 2017-10-01 Impact factor: 3.731
Authors: Oche O Agbaji; Maxwell O Akanbi; Ihedinachi Otoh; Patricia A Agaba; Rolake Akinsola; Victoria Okolie; Placid O Ugoagwu; Aliyu A Babadoko; Adewumi Adediran; Finomo O Finomo; Jonah O Abah; Haruna M Muktar; Alani S Akanmu Journal: Niger Postgrad Med J Date: 2019 Oct-Dec
Authors: Daniel F Carr; Mas Chaponda; Elena M Cornejo Castro; Andrea L Jorgensen; Saye Khoo; Joep J Van Oosterhout; Collet Dandara; Elizabeth Kampira; Francis Ssali; Paula Munderi; David G Lalloo; Robert S Heyderman; Munir Pirmohamed Journal: J Antimicrob Chemother Date: 2014-08-20 Impact factor: 5.790
Authors: Veronica Mulenga; Victor Musiime; Adeodata Kekitiinwa; Adrian D Cook; George Abongomera; Julia Kenny; Chisala Chabala; Grace Mirembe; Alice Asiimwe; Ellen Owen-Powell; David Burger; Helen McIlleron; Nigel Klein; Chifumbe Chintu; Margaret J Thomason; Cissy Kityo; A Sarah Walker; Diana M Gibb Journal: Lancet Infect Dis Date: 2015-10-05 Impact factor: 25.071
Authors: Daniel F Carr; Stephane Bourgeois; Mas Chaponda; Louise Y Takeshita; Andrew P Morris; Elena M Cornejo Castro; Ana Alfirevic; Andrew R Jones; Daniel J Rigden; Sam Haldenby; Saye Khoo; David G Lalloo; Robert S Heyderman; Collet Dandara; Elizabeth Kampira; Joep J van Oosterhout; Francis Ssali; Paula Munderi; Giuseppe Novelli; Paola Borgiani; Matthew R Nelson; Arthur Holden; Panos Deloukas; Munir Pirmohamed Journal: J Antimicrob Chemother Date: 2017-04-01 Impact factor: 5.790
Authors: Louise Warnich; Britt I Drögemöller; Michael S Pepper; Collet Dandara; Galen E B Wright Journal: Curr Pharmacogenomics Person Med Date: 2011-09